Bard Port Catheter lawsuit update

Verified snapshot

The facts that anchor this dossier

Implanted ports make repeated treatment possible without repeated peripheral needle access. MDL 3081 concerns allegations that certain Bard catheter materials can degrade, fracture, migrate, thrombose, or contribute to infection—and is now in active bellwether proceedings.

Federal proceeding

MDL 3081

District of Arizona before Senior Judge David G. Campbell.

Actions pending

3,564

JPML inventory as of July 1, 2026; 3,784 historical actions.

Centralized

August 8, 2023

The JPML transferred an initial ten actions and noted 38 potential tag-alongs.

Core allegations

Fracture, migration, infection, thrombosis

Allegations are contested and are not findings about every Bard port.

Bellwether posture

First trial preparations underway in 2026

A March 2026 order addressed final-pretrial work for the Cook bellwether and later cases.

Documented chronology

How the litigation reached this point

Why an implanted port is used

A totally implantable venous access port has a reservoir placed under the skin and a catheter that reaches a central vein. It can spare a patient from repeated peripheral IV placement during chemotherapy, infusions, blood draws, apheresis, or other long-term therapy. Some Bard PowerPort systems are also cleared for power injection of contrast when the correct access needle, pressure, and flow conditions are used.

The port and the catheter are different parts of one system. The reservoir is accessed through the skin; the catheter carries fluid into the circulation. A problem can occur at the connection, along the catheter, at the tip, or in the surrounding vein. Port dysfunction can reflect a mechanical issue, clot, malposition, infection, or an access problem. That is why a notation such as 'won't flush' is a starting clue rather than a diagnosis.

FDA clearance is not a guarantee that no complication will occur, and a recall for a defined model or manufacturing issue is not proof that all related products share the issue. Exact model, reference number, catheter material, implant date, and lot information—when available—are the only responsible way to connect a patient record to regulatory history.

What plaintiffs allege and defendants contest

The JPML's August 2023 order says the centralized actions share allegations that the catheter component contains a concentration of barium sulfate that reduces material integrity and can lead to infection, fracture, migration, and thrombosis. It also identified common questions about design, testing, monitoring, adverse-event reporting, and warnings. The order reports the allegations so it can decide whether cases share facts; it does not adopt them as true.

Port-catheter fracture and migration are recognized medical events beyond this litigation. A published series of 73 fractures across several brands found that most occurred near the port-catheter connection, and difficulty with injection was a common presentation. Case reports describe fragments migrating into the heart or pulmonary artery. These publications show that the event is medically plausible and warrants evaluation; they do not prove the MDL's product-specific material theory or identify the cause of an individual fracture.

FDA's MAUDE database also contains Bard reports describing fracture and migration. MAUDE is a signal-detection system. Reports may be submitted by manufacturers, clinicians, patients, or lawyers, and FDA cautions that the database cannot establish incidence or causation. It is useful for identifying reported event types, not for calculating the chance that a port will fail.

The bellwether process is now concrete

MDL 3081 moved from centralization to a structured bellwether program. In May 2025, the Arizona court selected six cases—Miller, Cook, Hicks, Divelbliss, Lattanzio, and Sorensen—plus James as an alternate. A later order set the anticipated order of trials. The cases include different asserted event types so the process can test recurring evidence rather than present one event as representative of the entire docket.

By March 2026, CMO 46 was addressing exhibit sealing, deposition designations, motions in limine, possible bifurcation, and courtroom access for the Cook trial. It also noted that Miller was one of only two thrombus cases in the pool and that Divelbliss was a fracture case. This level of pretrial detail shows active litigation; it is not evidence that liability or damages have been decided.

The July 2026 JPML report lists 3,564 pending actions out of 3,784 historical actions. A bellwether verdict or resolution, when it occurs, will concern the selected case under its evidence and governing law. It may inform the parties, but it cannot be converted into an automatic value for thousands of other cases.

Building a reliable device chronology

The operative report, implant card, explant report, and hospital supply record can identify the port and catheter. Imaging may show tip position, fracture, migration, thrombosis, extravasation, or a retained fragment. Interventional-radiology notes explain what clinicians observed during removal or retrieval. Culture results and infectious-disease records matter when infection is alleged. Oncology records can explain why the port was still needed and whether therapy could continue through another route.

Symptoms and timelines vary. Difficulty flushing or drawing blood, swelling, pain near the port, fever, arm or neck swelling, and changes during infusion deserve medical evaluation. Chest pain or shortness of breath can be urgent. This dossier cannot determine whether a symptom came from a catheter, a blood clot, infection, cancer treatment, or another condition.

For litigation tracking, use the District of Arizona's case-of-interest repository and the signed PDF orders, not a copied trial date on a marketing page. For personal legal questions, product proof and state-specific timing rules must be reviewed together. The existence of an implanted Bard port or a reported complication does not by itself establish eligibility or a future payment.

Reader questions

Frequently asked questions